A thymic hormone protects mice from enteropathy during acute graft-versus-host disease.

Inagaki-Ohara K, Sakai T, Koya G, Awaya A, Yoshikai Y

Microbiology and immunology1 Jan 1997Cited by 2 (Europe PMC)

PMID9444331DOI10.1111/j.1348-0421.1997.tb01945.xPepBankPUB-09444331

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with acute GVHD, FTS reduced mortality.
In plain wordsIn mice with graft-versus-host disease, FTS reduced deaths compared with no FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseMortality
Study
mousen: not reported in source
Acute graft-versus-host disease after parental splenocyte transfer
Comparator
GVHD without FTS
Outcome group
Mortality · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
FTS treatment significantly protected mice from developing acute GVHD as assessed by mortality rate, splenomegaly and enteropathy.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids.
Report a problemFND-0944433101
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with acute GVHD, FTS reduced splenomegaly.
In plain wordsIn mice with graft-versus-host disease, FTS reduced spleen enlargement compared with no FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseSplenomegaly
Study
mousen: not reported in source
Acute graft-versus-host disease after parental splenocyte transfer
Comparator
GVHD without FTS
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
FTS treatment significantly protected mice from developing acute GVHD as assessed by mortality rate, splenomegaly and enteropathy.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids.
Report a problemFND-0944433102
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with acute GVHD, FTS reduced enteropathy.
In plain wordsIn mice with graft-versus-host disease, FTS reduced intestinal disease compared with no FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseEnteropathy
Study
mousen: not reported in source
Acute graft-versus-host disease after parental splenocyte transfer
Comparator
GVHD without FTS
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
FTS treatment significantly protected mice from developing acute GVHD as assessed by mortality rate, splenomegaly and enteropathy.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids.
Report a problemFND-0944433103
04AnimalAnimal study (in vivo)Mechanism
In mice with acute GVHD, FTS inhibited intestinal infiltration by donor-derived TCR alpha beta intraepithelial lymphocytes bearing CD8 alpha beta.
In plain wordsIn mice with graft-versus-host disease, FTS reduced donor T cell infiltration in the intestine compared with no FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseDonor-derived intestinal T cell infiltration
Study
mousen: not reported in source
Acute graft-versus-host disease after parental splenocyte transfer
Comparator
GVHD without FTS
Outcome group
Immune response · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The infiltration of donor-derived TCR alpha beta i-IEL bearing CD8 alpha beta was significantly inhibited in the small intestine of FTS-treated mice, and the frequencies of apoptosis of crypt cells in the intestinal mucosa were decreased in these mice during acute GVHD.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids.
Report a problemFND-0944433104
05AnimalAnimal study (in vivo)Mechanism
In mice with acute GVHD, FTS reduced intestinal crypt cell apoptosis.
In plain wordsIn mice with graft-versus-host disease, FTS reduced intestinal crypt cell death compared with no FTS.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIntestinal crypt cell apoptosis
Study
mousen: not reported in source
Acute graft-versus-host disease after parental splenocyte transfer
Comparator
GVHD without FTS
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The infiltration of donor-derived TCR alpha beta i-IEL bearing CD8 alpha beta was significantly inhibited in the small intestine of FTS-treated mice, and the frequencies of apoptosis of crypt cells in the intestinal mucosa were decreased in these mice during acute GVHD.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids.
Report a problemFND-0944433105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.